Fevara plc (LSE: FVA), the international livestock supplements specialist, has announced that Gillian Watson, its Senior Independent Non-Executive Director, will not seek re-election at the Company's next Annual General Meeting, expected to be held in February 2027. Watson joined the Board in October 2023 and will retire upon conclusion of the AGM. The departure removes a key independent voice from the board of a company that has undergone significant structural change in recent years, and investors may be watching how Fevara plans to address the resulting board composition.

Key Points

  • Fevara plc (FVA) is an international specialist in livestock supplements listed on the London Stock Exchange since 1972
  • Senior Independent Non-Executive Director Gillian Watson has confirmed she will not seek re-election at the next AGM, expected in February 2027
  • Watson joined the Board in October 2023; adjusted operating profit is expected to have nearly tripled since her first full year on the Board, according to the announcement
  • Investors should watch for any announcement regarding Watson's replacement as Senior Independent Non-Executive Director

Gillian Watson's Planned Departure from Fevara's Board Ahead of February 2027 AGM

Fevara plc confirmed on 20 November 2026 that Gillian Watson has informed the Company she will not seek re-election at the forthcoming AGM, anticipated to take place in February 2027. Watson has served as Senior Independent Non-Executive Director since October 2023, a role that carries particular significance in UK corporate governance as a key point of contact for shareholders on matters where normal channels may be inappropriate. Her departure will take effect at the conclusion of the AGM, and no successor has been named in the announcement.

Non-Executive Chair Tim Jones and Watson Both Cite a Period of Group Transformation

Non-Executive Chair Tim Jones expressed gratitude for Watson's contribution, noting her support and counsel since she joined. In her own remarks, included in the announcement, Watson highlighted that the Group has reshaped itself from Carr's Group into Fevara during her tenure, describing this as a period of significant transition and stabilisation. She also noted that adjusted operating profit is expected to have nearly tripled since her first full year on the Board. The Company did not disclose specific absolute figures for adjusted operating profit in the announcement.

Fevara's Business: Livestock Supplements Across More Than 20 Countries

Fevara develops, manufactures and markets research-proven livestock supplements, including feed licks, blocks, bagged minerals, and boluses for cattle, sheep and horses. Its portfolio includes well-known brands such as Crystalyx, Horslyx, Scotmin Nutrition, SmartLic, Tracesure Advanced and Macal. Headquartered in Carlisle, Cumbria, the Group operates six sites across Brazil, the UK, and the USA, with three joint ventures in Germany, the UK, and the USA. Products are sold in more than 20 countries through Fevara's international distribution network.

Board Succession and Governance Risk Following Watson's Exit

The loss of a Senior Independent Non-Executive Director introduces a governance consideration for Fevara, as this role is specifically required under the UK Corporate Governance Code for companies of a certain size and structure. The announcement does not confirm whether a search for a successor is under way, nor does it indicate any change to the broader composition of the Board. Investors may be watching for further updates on board succession planning ahead of the February 2027 AGM.